Nurix Therapeutics Announces Second Research Term Extension for Oncology Program Under Collaboration with Gilead Sciences
Globe Newswire•05/10/2026•07:00 ET
0
Key Highlights
- ➤Nurix and Gilead extend undisclosed oncology program research term by two years
- ➤Nurix receives $10 million research term extension fee
- ➤Nurix retains U.S. 50/50 profit-sharing options on up to two programs
- ➤Nurix eligible for approximately $1.3 billion in additional collaboration payments
- ➤GS-6791, an oral IRAK4 degrader, advances in Phase 1 clinical development
Expert Statements
Gwenn M. Hansen, Chief Scientific Officer of Nurix Therapeutics
“Gilead’s decision to extend the research term for this program reflects our longstanding commitment to productive collaborations, the outstanding dedication of our research teams, and the potential of Nurix’s targeted protein degradation platform to generate novel medicines against therapeutically important targets.”
Gwenn M. Hansen, Chief Scientific Officer of Nurix Therapeutics
“Our collaboration has already advanced GS-6791, an oral IRAK4 degrader discovered by Nurix, into clinical development, and we are pleased to continue working with Gilead to discover and advance additional drug candidates across oncology and inflammatory diseases.”
Gwenn M. Hansen, Chief Scientific Officer of Nurix Therapeutics
“This extension provides further evidence of the value of the collaboration and the capabilities of our platform.”
Two-year extension builds on productive relationship established in 2019
Nurix continues to retain co-development and 50/50 profit sharing options on up to two programs in the United States
Get started
Create a free account to read the full story.